S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)|
|P||Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)|
|P||Morningstar Stock Analyst Reports (full research on 2,000 stocks)|
|P||Morningstar Stock and Fund Stewardship Grades|
|P||Portfolio Manager (advanced with 10 x-ray analyses, including guidance)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Synthetic Biologics Reports First Quarter 2013 Financial Results (2013/5/15)|
|Synthetic Biologics Reports Year End 2012 Financial Results (2013/4/16)|
|Infectious Disease Specialist, Brad Spellberg, M.D., Joins Synthetic Biologics' Scientific Advisory Board (2013/2/26)|
|Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S. (2013/2/22)|
|Synthetic Biologics Announces Issuance of U.S. Patent Covering Combination of Estriol and Copaxone® for Multiple Sclerosis (2013/4/4)|
|Synthetic Biologics to Present at the 25th Annual ROTH Conference (2013/3/12)|
|ZIOPHARM Terminates Development of Palifosfamide in Metastatic Soft Tissue Sarcoma (2013/3/26)|
|Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect (2013/4/19)|
|Gen9 Receives $21 Million Strategic Investment From Agilent Technologies (2013/4/24)|
|Life Technologies Launches New Bioinformatics Software Platform Enabling Bio-Design and Gene Synthesis from Next Generation Sequencing Data (2013/4/11)|
Click above to view more mutual fund data and stats for syn - Synthetic Biologics Inc.